OBJECTIVE:

• The objective of this SOP is to outline the procedures for conducting Quality Management Review Meetings. These meetings aim to ensure continuous improvement, compliance with regulatory requirements, and the enhancement of overall quality management practices.

SCOPE:

• This SOP applies to all departments and personnel involved in quality-related activities, including but not limited to Quality Assurance, Quality Control, Regulatory Affairs, Pharmacovigilance, Production, Engineering, and Warehouse. It covers the review of:
• • • Quality metrics (complaints, deviations, CAPAs, OOS, audit findings, recalls).
    • Compliance status with regulatory and customer requirements.
    • Risk management activities.
    • Effectiveness of corrective and preventive actions.
    • Continuous improvement initiatives.

RESPONSIBILITIES:

• Senior Management:
• • • Ensure active participation in QMR meetings.
    • Review adequacy of resources, facilities, and training.
    • Approve strategic quality improvement actions.

• Head Quality Assurance (QA) / Designee:
  • Schedule QMR meetings at defined intervals.
  • Compile and circulate agenda, metrics, and reports in advance.
  • Lead the meeting, record minutes, assign action items, and follow up on closure.

• Department Heads:
  • Present performance metrics, compliance issues, and improvement initiatives.
  • Support risk assessment and mitigation planning.
  • Ensure timely implementation of action items assigned.

DEFINATIONS:

• Quality Management Review (QMR): A formal, documented meeting conducted by senior management and relevant stakeholders to evaluate the performance and effectiveness of the Pharmaceutical Quality System (PQS), identify improvement opportunities, and ensure compliance with GMP and regulatory requirements.

• Pharmaceutical Quality System (PQS): A comprehensive system for implementing quality management principles in the pharmaceutical industry, as described in EU GMP Chapter 1 and ICH Q10, to ensure products are consistently of the required quality.

• Corrective and Preventive Action (CAPA): A systematic process for investigating and eliminating the root cause of identified problems (Corrective Action) and preventing their recurrence (Preventive Action).

• Key Performance Indicators (KPIs): Measurable values used to monitor, control, and improve quality system performance (e.g., number of deviations, CAPA closure timelines, complaint trends).

• Deviation: Departure from an approved instruction, standard, or procedure that may impact product quality, regulatory compliance, or safety.

• Out of Specification (OOS): A test result that falls outside the established acceptance criteria defined in regulatory filings, pharmacopoeias, or internal specifications.

• Non-Conformance: Failure to meet specified requirements, standards, or expectations, which may include deviations, audit findings, or regulatory deficiencies.

• Change Control: A documented process to manage and evaluate any modification to facilities, equipment, processes, or documents, ensuring the change does not adversely affect product quality or compliance.

• Quality Risk Management (QRM): A systematic process for identifying, analyzing, and controlling potential risks to product quality, as described in ICH Q9.

• Market Complaint: Any reported dissatisfaction from customers, patients, or healthcare professionals regarding the quality, safety, or performance of a marketed product.
• Pharmacovigilance (PV): The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other medicine-related safety concerns.

• Management Review Output: The documented outcomes of the QMR meeting, including decisions, action items, resource requirements, and commitments for continuous improvement.

PROCEDURE:

Frequency:

• A formal Management Review Meeting shall be conducted at least annually in line with EU GMP and ICH Q10.

Meeting Preparation

• QA designee shall prepare the agenda and circulates it one week in advance.
• Department head shall submit departmental data well advance before the meeting.
• Designee QA shall compile, verify, and circulate the departmental data with all stakeholders before the meeting.

Conducting the Meeting:

• The agenda shall include but not be limited to:
• • • Review of previous meeting minutes and status of action items.
    • Quality metrics: deviations, CAPAs, complaints, OOS, recalls, audit findings.
    • Regulatory Affairs & Pharmacovigilance activities.
    • Assessment of Quality Risk Management activities.
    • Review of changes (Change Control), validations, and technology transfers.
    • Resource adequacy (manpower, facilities, training).
    • Continuous improvement initiatives.
    • Approval of new CAPAs and preventive actions.

Documentation & Follow-Up:

• Minutes shall record all discussions, decisions, assigned responsibilities, and timelines.
• Action items must be tracked to closure; unresolved actions shall be escalated to senior management.
• A summary report of the QMR shall be signed by QA Head.

Communication & Training:

• Relevant outcomes impacting operations shall be communicated to staff through training or awareness sessions.

REFERENCES:

• EudraLex – Volume 4,
• ICH Q10 – Pharmaceutical Quality System:
• WHO Technical Report Series (TRS) 986, Annex 2

RECORDS:

REVISION HISTORY.